# Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

> **NCT02344290** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 7769 (actual)

## Conditions studied

- HIV
- Cardiovascular Diseases

## Interventions

- **DRUG:** Pitavastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02344290
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-26
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 7769 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344290, "Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02344290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*